Skip to main content
. 2023 Jul 25;24(15):11887. doi: 10.3390/ijms241511887

Table 3.

Tumor-mutation-burden-based biomarkers for ICIs response in NSCLC.

Biomarker Method Key Finding
TMB cfDNA Patients with baseline TMB > 16/Mb displaying longer OS in a long-term follow-up after ICI treatment [82].
TMB Genomic sequencing ICI-treated patients with TMB > 10/Mb exhibit increased PFS [85].
ICI-treated patients with higher TMB rates present higher PFS [86].
Atezolizumab-treated patients with TMB > 13.6/Mb showed improved PFS as compared to chemotherapy-treated patients [84].

TMB—tumor mutation burden; cfDNA—cell free DNA; OS—overall survival; ICI—immune checkpoint inhibitor; PFS—progression free survival; bTMB—blood-based tumor mutation burden.